(Q37781731)

23 August 2017

title

Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma? (English)

1 reference

23 August 2017

Allogeneic Hematopoietic Stem Cell Transplantation: Does It Have a Place in Treating Hodgkin Lymphoma? (English)

1 reference

https://api.crossref.org/works/10.1007/S11899-010-0065-7

stem cell transplantation

21 June 2024

main subject

1 reference

3

Steven Z Pavletic

1 reference

23 August 2017

Rachel B. Salit

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20730513

21 June 2024

Michael R. Bishop

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20730513

21 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20730513

21 June 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

http://link.springer.com/content/pdf/10.1007/s11899-010-0065-7.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S11899-010-0065-7

http://link.springer.com/article/10.1007/s11899-010-0065-7/fulltext.html

21 June 2024

1 reference

https://api.crossref.org/works/10.1007/S11899-010-0065-7

http://link.springer.com/content/pdf/10.1007/s11899-010-0065-7

21 June 2024

1 reference

https://api.crossref.org/works/10.1007/S11899-010-0065-7

Current hematologic malignancy reports

21 June 2024

published in

1 reference

23 August 2017

volume

5

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

229-238

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-010-0065-7

23 August 2017

exact match

0 references

cites work

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group

1 reference

12 December 2020

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

1 reference

12 December 2020

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.

1 reference

12 December 2020

Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute

1 reference

12 December 2020

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

12 December 2020

Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.

1 reference

12 December 2020

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

1 reference

12 December 2020

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

1 reference

12 December 2020

Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody

1 reference

12 December 2020

Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation

1 reference

12 December 2020

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

1 reference

12 December 2020

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

1 reference

12 December 2020

Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up

1 reference

12 December 2020

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

1 reference

12 December 2020

Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.

1 reference

12 December 2020

Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.

1 reference

12 December 2020

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

1 reference

12 December 2020

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

1 reference

12 December 2020

1 reference

12 December 2020

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

1 reference

12 December 2020

Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma

1 reference

12 December 2020

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

12 December 2020

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

12 December 2020

Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin

1 reference

12 December 2020

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

1 reference

12 December 2020

Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.

1 reference

12 December 2020

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

1 reference

12 December 2020

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

1 reference

12 December 2020

New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group

1 reference

12 December 2020

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.

1 reference

12 December 2020

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group

1 reference

12 December 2020

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

1 reference

12 December 2020

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma

1 reference

12 December 2020

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

12 December 2020

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

1 reference

12 December 2020

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

1 reference

12 December 2020

Current treatment and immunotherapy of Hodgkin's lymphoma.

1 reference

12 December 2020

Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation

1 reference

12 December 2020

ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results

1 reference

12 December 2020

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

12 December 2020

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol

1 reference

12 December 2020

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.

1 reference

12 December 2020

Journal of Clinical Oncology

37

20

221

A Josting

2002

1 reference

https://api.crossref.org/works/10.1007/S11899-010-0065-7

21 June 2024

40

90

1680

B Klimm

2005

1 reference

https://api.crossref.org/works/10.1007/S11899-010-0065-7

21 June 2024

Identifiers

1 reference

23 August 2017

1 reference